Metrics as of 10/14/2026, 04:09 PM (Berlin time), refresh in progress.
Ocular Therapeutix Stock
Ocular Therapeutix, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Pravin U. Dugel
- Employees
- 325
- Market cap
- $1.6 B
- IPO
- 25/07/2014
Ocular Therapeutix, Inc. is a healthcare company in the biotechnology industry, headquartered in Bedford, US. Founded in 2006, the biopharmaceutical company specializes in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Ocular Therapeutix stock: price history
1D
-0.1%
1W
+0.1%
1M
-32.5%
6M
-18.8%
YTD
-40.4%
1Y
-35.6%
2Y
-30.8%
5Y
-35.3%
10Y
+6.6%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~1% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Ocular Therapeutix
Analyst assessment of Ocular Therapeutix
PRICE TARGET LOW
US$14.00
CONSENSUS
US$23.00
MEDIAN
US$25.00
PRICE TARGET HIGH
US$30.00
1
STRONG BUY
16
BUY
2
HOLD
0
SELL
0
STRONG SELL
19
TOTAL · Buy
As of: 02/10/2026
Ocular Therapeutix stock metrics
P/E
-5.09
P/B
3.13
EV/EBITDA
-3.73
RETURN ON EQUITY
-15.1%
NET MARGIN
-584.5%
DEBT/EQUITY
0.15
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
84.4%
FLOAT SHARES
184,902,977
AVG. DAILY VOLUME (30D)
3,340,000
Insider transactions (SEC)
Anderman Todd
Kaiser Peter
Heier Jeffrey S.
Notman Donald
Heier Jeffrey S.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -0.1%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Ocular Therapeutix stock
What does Ocular Therapeutix do?
Ocular Therapeutix, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Pravin U. Dugel, the company employs around 325 people.
The IPO was on 25/07/2014; the stock trades on NASDAQ under the ticker OCUL.
What do analysts say about Ocular Therapeutix stock?
19 analysts rate the stock, the consensus is Buy (as of 02/10/2026).
The average price target is US$23.00, ranging from US$14.00 to US$30.00, with a median of US$25.00.
This is an external assessment, not a statement by Market Jury.
When does Ocular Therapeutix report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 1% stronger than usual.
Does Ocular Therapeutix pay a dividend?
No, Ocular Therapeutix currently does not pay a dividend.
Which stocks are comparable to Ocular Therapeutix?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Ocular Therapeutix stock analyzed?
Clicking "Analyze stock" lets five strategies assess Ocular Therapeutix against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.